Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Melilotus officinalis pollen is derived from the plant commonly known as yellow sweetclover or sweet clover, a species of legume native to Eurasia. Traditionally, extracts from *Melilotus officinalis* (including parts of the flowering plant) have been used for their medicinal properties, particularly in treating venous circulation disorders, edema, hemorrhoids, and varicose veins. The plant contains active compounds such as coumarins (which can convert to dicoumarol, a potent anticoagulant), flavonoids, and phenolic acids. These constituents contribute to its reported anti-inflammatory, antiedematous, and antioxidant effects. While the pollen itself is also recognized as a mild allergen, the plant's extracts are utilized in various herbal remedies and dietary supplements for their purported benefits in improving lymphatic function, increasing venous return, and acting as a mild anticoagulant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Melilotus officinalis pollen.